301
44.
22.
Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis Delta virus
infection. Curr Infect Dis Rep (2013) 15:31–38
23.
Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, et al. In vivo antiviral efficacy of
prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003;112:407–14.
24.
Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, et al. Prevention of
hepatitis B virus infection in vivo by entry inhibitors derived from the large
envelope protein. Nat Biotechnol. 2008;26:335–41.
25.
Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, et al. Humanized
chimeric uPA mouse model for the study of hepatitis B and D virus interactions
and preclinical drug evaluation. Hepatology. 2012;55:685–94.
26.
Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, et al. Phase 1b study of
pegylated interferon lambda 1 with or without ribavirin in patients with chronic
genotype 1 hepatitis C virus infection. Hepatology. 2010;52:822–32.
27.
Türkiye Kronik Viral Hepatit Taný ve Tedavi Rehberi 2015; S 29-36
HDV Enfeksiyonu: Tedavi
